Source: Eur Respir J, 53 (2) 1800948; 10.1183/13993003.00948-2018
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
William W. Busse, Guy G. Brusselle, Stephanie Korn, Piotr Kuna, Antoine Magnan, David Cohen, Karin Bowen, Teresa Piechowiak, Millie M. Wang, Gene Colice. Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma. Eur Respir J, 53 (2) 1800948; 10.1183/13993003.00948-2018

Member's Comments

No comment yet.

Related content which might interest you: Real-world oral glucocorticoid-sparing effect of benralizumab in severe asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma Source: Eur Respir J, 55 (1) 1901147; 10.1183/13993003.01147-2019 Year: 2020 Oral corticosteroids in the treatment of exacerbation of severe asthma Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden Year: 2020 Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma Source: International Congress 2017 – Asthma management Year: 2017 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003 Nebulizer therapy with budesonide in addition to systemic corticosteroids in acute severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 541s Year: 2004 The efficacy of omalizumab in severe in asthma after treatment withdrawal Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma Source: Eur Respir J 2001; 17: 374-379 Year: 2001 Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003 Omalizumab, a novel therapy for severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 lnhaled long-acting beta-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005 Response of children with bronchial asthma to combined therapy with an oral immunostimulating drug and antileukotrienes Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005 Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019 Year: 2020 To assess the effects of combined nasal and inhaled corticosteroid in patients with asthma and persistent allergic rhinitis Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009 The new approaches to the oral corticosteroid dosage decrease in patients with severe steroid-resistant bronchial asthma Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population Year: 2005 Adding slow-released theophyllne to inhaled corticosteroids in the treatment of mild persistent asthma Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007